Details for New Drug Application (NDA): 021721
✉ Email this page to a colleague
The generic ingredient in LEVAQUIN is levofloxacin. There are thirty-one drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the levofloxacin profile page.
Summary for 021721
Tradename: | LEVAQUIN |
Applicant: | Janssen Pharms |
Ingredient: | levofloxacin |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 021721
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SOLUTION;ORAL | Strength | 250MG/10ML | ||||
Approval Date: | Oct 21, 2004 | TE: | RLD: | Yes |
Expired US Patents for NDA 021721
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Janssen Pharms | LEVAQUIN | levofloxacin | SOLUTION;ORAL | 021721-001 | Oct 21, 2004 | ⤷ Subscribe | ⤷ Subscribe |
Janssen Pharms | LEVAQUIN | levofloxacin | SOLUTION;ORAL | 021721-001 | Oct 21, 2004 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription